LT3277677T - 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai - Google Patents
1-ciano-pirolidino junginiai kaip usp30 inhibitoriaiInfo
- Publication number
- LT3277677T LT3277677T LTEP16713043.4T LT16713043T LT3277677T LT 3277677 T LT3277677 T LT 3277677T LT 16713043 T LT16713043 T LT 16713043T LT 3277677 T LT3277677 T LT 3277677T
- Authority
- LT
- Lithuania
- Prior art keywords
- cyano
- pyrrolidine compounds
- usp30 inhibitors
- usp30
- inhibitors
- Prior art date
Links
- 101150099494 Usp30 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1505429.9A GB201505429D0 (en) | 2015-03-30 | 2015-03-30 | Novel compounds |
| GBGB1512829.1A GB201512829D0 (en) | 2015-07-21 | 2015-07-21 | Novel compounds |
| PCT/GB2016/050851 WO2016156816A1 (en) | 2015-03-30 | 2016-03-24 | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3277677T true LT3277677T (lt) | 2021-05-25 |
Family
ID=55646790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP16713043.4T LT3277677T (lt) | 2015-03-30 | 2016-03-24 | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10343992B2 (enExample) |
| EP (3) | EP3277677B9 (enExample) |
| JP (3) | JP6708661B2 (enExample) |
| KR (1) | KR102578325B1 (enExample) |
| CN (2) | CN112707893B (enExample) |
| AU (1) | AU2016240033B2 (enExample) |
| BR (1) | BR112017020900B1 (enExample) |
| CA (1) | CA2976741C (enExample) |
| CO (1) | CO2017011172A2 (enExample) |
| CY (1) | CY1124170T1 (enExample) |
| DK (1) | DK3277677T3 (enExample) |
| ES (1) | ES2864950T3 (enExample) |
| HR (1) | HRP20210791T2 (enExample) |
| HU (1) | HUE054474T2 (enExample) |
| IL (1) | IL254721B (enExample) |
| LT (1) | LT3277677T (enExample) |
| MD (1) | MD3277677T2 (enExample) |
| MX (1) | MX373656B (enExample) |
| MY (1) | MY188957A (enExample) |
| NZ (1) | NZ736450A (enExample) |
| PL (1) | PL3277677T3 (enExample) |
| PT (1) | PT3277677T (enExample) |
| RS (1) | RS61759B9 (enExample) |
| RU (1) | RU2717238C2 (enExample) |
| SG (1) | SG11201706542TA (enExample) |
| SI (1) | SI3277677T1 (enExample) |
| SM (1) | SMT202100287T1 (enExample) |
| WO (1) | WO2016156816A1 (enExample) |
| ZA (1) | ZA201705717B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| MD3277677T2 (ro) * | 2015-03-30 | 2021-07-31 | Mission Therapeutics Ltd | Compuși de 1-ciano-pirolidină utilizați ca inhibitori de USP30 |
| GB201521109D0 (en) * | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) * | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) * | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| JP6959332B2 (ja) | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) * | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| WO2018213150A1 (en) * | 2017-05-15 | 2018-11-22 | Mitobridge, Inc. | Usp30 inhibitors |
| GB201708652D0 (en) * | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN110831936B (zh) * | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
| ES2950757T3 (es) * | 2017-10-06 | 2023-10-13 | Forma Therapeutics Inc | Inhibición de la peptidasa específica de la ubiquitina 30 |
| BR112020021921A2 (pt) | 2018-05-17 | 2021-01-26 | Forma Therapeutics, Inc. | compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina |
| US11572374B2 (en) * | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| LT3860989T (lt) * | 2018-10-05 | 2023-06-12 | Forma Therapeutics, Inc. | Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) * | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| EP4126853A1 (en) * | 2020-03-30 | 2023-02-08 | The Scripps Research Institute | Small molecule inhibitors of influenza hemagglutinin |
| CN111303128B (zh) * | 2020-04-07 | 2020-10-27 | 苏州信诺维医药科技有限公司 | 一种多环类化合物、其制备方法及应用 |
| KR20230006487A (ko) * | 2020-04-08 | 2023-01-10 | 미션 테라퓨틱스 엘티디 | Usp30 억제제로서의 활성을 갖는 n-시아노피롤리딘 |
| MX2022014429A (es) * | 2020-05-28 | 2022-12-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| US20230303547A1 (en) * | 2020-06-04 | 2023-09-28 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| HUE072598T2 (hu) * | 2020-06-08 | 2025-11-28 | Mission Therapeutics Ltd | 1-(5-(2-cianopiridin-4-il)oxazol-2-karbonil)-4-metilhexahidropirrolo[3,4-B]pirrol-5(1H)-karbonitril felhasználásra, mint USP30 inhibitor, mitokondriális diszfunkció, rák és fibrózisok kezelésében |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| US20240059673A1 (en) * | 2020-12-22 | 2024-02-22 | Gilead Sciences, Inc. | Substituted indole compounds |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN117957234A (zh) | 2021-09-10 | 2024-04-30 | 吉利德科学公司 | 噻吩并吡咯化合物 |
| AU2022362107A1 (en) | 2021-10-11 | 2024-05-02 | Anebulo Pharmaceuticals, Inc. | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
| EP4441044A1 (en) | 2021-12-01 | 2024-10-09 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| WO2024086708A2 (en) * | 2022-10-19 | 2024-04-25 | Ohio State Innovation Foundation | Compositions and methods for preventing cardiomyopathy |
| TW202446368A (zh) * | 2023-02-28 | 2024-12-01 | 美商賽堤爾醫療公司 | 經取代之吡咯啶及吡咯啶酮化合物 |
| CN119528901A (zh) * | 2024-11-05 | 2025-02-28 | 上海市同济医院 | 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| EP1272467A4 (en) | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine protease inhibitors |
| WO2004022536A1 (en) | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| KR100944301B1 (ko) * | 2005-02-22 | 2010-02-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Ｍｄｍ２의 소분자 억제제 및 이의 용도 |
| AR071480A1 (es) * | 2008-04-18 | 2010-06-23 | Glaxo Group Ltd | Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd ) |
| HUE060249T2 (hu) | 2008-06-16 | 2023-02-28 | Univ Tennessee Res Found | Vegyületek rák kezelésére |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| CA2741666C (en) | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| EP2410858B1 (en) | 2009-03-23 | 2016-09-07 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| CN103261169A (zh) * | 2010-09-24 | 2013-08-21 | 密歇根大学董事会 | 脱泛素酶抑制剂及其应用方法 |
| KR102022575B1 (ko) * | 2011-10-19 | 2019-09-18 | 비보룩스 아베 | 탈유비퀴틴화 활성의 저해 방법 |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| AU2014239542A1 (en) | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US10160727B2 (en) | 2014-08-06 | 2018-12-25 | Shionogi & Co., Ltd. | Heterocycle and carbocycle derivatives having TrkA inhibitory activity |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| MD3277677T2 (ro) * | 2015-03-30 | 2021-07-31 | Mission Therapeutics Ltd | Compuși de 1-ciano-pirolidină utilizați ca inhibitori de USP30 |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| JP6959332B2 (ja) * | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
-
2016
- 2016-03-24 MD MDE20180120T patent/MD3277677T2/ro unknown
- 2016-03-24 WO PCT/GB2016/050851 patent/WO2016156816A1/en not_active Ceased
- 2016-03-24 JP JP2017551189A patent/JP6708661B2/ja active Active
- 2016-03-24 CN CN202110132842.2A patent/CN112707893B/zh active Active
- 2016-03-24 EP EP16713043.4A patent/EP3277677B9/en active Active
- 2016-03-24 ES ES16713043T patent/ES2864950T3/es active Active
- 2016-03-24 DK DK16713043.4T patent/DK3277677T3/da active
- 2016-03-24 HR HRP20210791TT patent/HRP20210791T2/hr unknown
- 2016-03-24 US US15/558,632 patent/US10343992B2/en active Active
- 2016-03-24 CA CA2976741A patent/CA2976741C/en active Active
- 2016-03-24 EP EP21190809.0A patent/EP3943490A1/en active Pending
- 2016-03-24 SM SM20210287T patent/SMT202100287T1/it unknown
- 2016-03-24 LT LTEP16713043.4T patent/LT3277677T/lt unknown
- 2016-03-24 RU RU2017134901A patent/RU2717238C2/ru active
- 2016-03-24 AU AU2016240033A patent/AU2016240033B2/en active Active
- 2016-03-24 CN CN201680019213.6A patent/CN107484415B/zh active Active
- 2016-03-24 KR KR1020177031166A patent/KR102578325B1/ko active Active
- 2016-03-24 HU HUE16713043A patent/HUE054474T2/hu unknown
- 2016-03-24 RS RS20210502A patent/RS61759B9/sr unknown
- 2016-03-24 MY MYPI2017001206A patent/MY188957A/en unknown
- 2016-03-24 SG SG11201706542TA patent/SG11201706542TA/en unknown
- 2016-03-24 BR BR112017020900-4A patent/BR112017020900B1/pt active IP Right Grant
- 2016-03-24 SI SI201631157T patent/SI3277677T1/sl unknown
- 2016-03-24 PL PL16713043T patent/PL3277677T3/pl unknown
- 2016-03-24 PT PT167130434T patent/PT3277677T/pt unknown
- 2016-03-24 NZ NZ736450A patent/NZ736450A/en unknown
- 2016-03-24 EP EP21156385.3A patent/EP3842427A1/en active Pending
- 2016-03-24 MX MX2017012566A patent/MX373656B/es active IP Right Grant
-
2017
- 2017-08-22 ZA ZA2017/05717A patent/ZA201705717B/en unknown
- 2017-09-26 IL IL254721A patent/IL254721B/en active IP Right Grant
- 2017-10-30 CO CONC2017/0011172A patent/CO2017011172A2/es unknown
-
2019
- 2019-03-11 US US16/297,937 patent/US11053198B2/en active Active
- 2019-05-22 US US16/419,558 patent/US10689345B2/en active Active
- 2019-05-22 US US16/419,747 patent/US11066365B2/en active Active
-
2020
- 2020-02-12 US US16/788,446 patent/US11390584B2/en active Active
- 2020-05-21 JP JP2020088995A patent/JP7216682B2/ja active Active
-
2021
- 2021-05-20 CY CY20211100441T patent/CY1124170T1/el unknown
-
2022
- 2022-03-31 US US17/709,556 patent/US20220251041A1/en active Pending
- 2022-06-21 JP JP2022099677A patent/JP7389856B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254721A0 (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
| IL250709A0 (en) | Aminopyrimidines and their use to inhibit jak | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| GB201510019D0 (en) | Compounds | |
| IL251780A0 (en) | New compounds as nik inhibitors | |
| GB201513481D0 (en) | Inhibitor compounds | |
| GB201508747D0 (en) | Compounds | |
| GB201514754D0 (en) | Compounds | |
| GB201505658D0 (en) | Inhibitor compounds | |
| GB201514751D0 (en) | Compounds | |
| SMT202100338T1 (it) | Composti | |
| GB201501004D0 (en) | Inhibitors | |
| GB201508864D0 (en) | Compounds | |
| GB201510493D0 (en) | Compounds | |
| GB201520949D0 (en) | Inhibitors | |
| GB201503926D0 (en) | Compounds | |
| GB201501115D0 (en) | Compounds | |
| GB201508857D0 (en) | Compounds | |
| GB201522453D0 (en) | Inhibitor compounds | |
| GB201520189D0 (en) | Compound for use | |
| GB201500644D0 (en) | Inhibitor compounds | |
| GB201511387D0 (en) | Compounds | |
| GB201511064D0 (en) | Compounds | |
| GB201510910D0 (en) | Compounds | |
| GB201510760D0 (en) | Compounds |